Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events

杜皮鲁玛 医学 特应性皮炎 荟萃分析 内科学 皮肤病科
作者
Gregory P. Geba,Dateng Li,Meng Xu,Kusha A Mohammadi,Richa Attre,Marius Ardeleanu,Bret J. Musser
出处
期刊:The Journal of Allergy and Clinical Immunology [Elsevier BV]
卷期号:151 (3): 756-766 被引量:113
标识
DOI:10.1016/j.jaci.2022.08.026
摘要

BACKGROUND: Atopic march refers to the sequential development of allergic diseases from infancy through adolescence, typically beginning with atopic dermatitis (AD), followed by food allergy and then airway diseases, later evolving to broader or worsened spectrum of allergic diatheses. No intervention has shown to alter its course. OBJECTIVE: We sought to determine the rate of acquisition of new or worsened allergic events for dupilumab versus placebo in patients with AD. METHODS: Allergy-associated events from 12 clinical trials were grouped into 17 allergy categories, and IgE changes from baseline were defined. A new/worsened event was considered one step of atopic march. Treatment effect was assessed by incidence rate ratios (IRRs), dupilumab versus placebo, by meta-analysis. RESULTS: The duration of pooled AD studies was 4 to 52 weeks (1359 patient-years; n = 2296 dupilumab, n = 1229 placebo, median age 35 years). The median age at AD onset was 2 years. Baseline allergic disease burden was comparable between groups. Dupilumab reduced the risk of new/worsening allergies by 34% (IRR 0.66; 95% confidence interval [CI], 0.52-0.84) and new allergies by 37% (IRR 0.63; 95% CI, 0.48-0.83) versus placebo. Including IgE category shift, the IRR for combined new/worsening allergies was reduced by 54% (IRR 0.46; 95% CI, 0.36-0.57). These treatment benefits did not reverse on treatment discontinuation in off-treatment follow-up. CONCLUSIONS: The acquisition/worsening of allergic conditions suggestive of atopic march was observed in a pooled adult/adolescent AD study population with inadequately controlled AD. Treatment with dupilumab reduced new/worsened allergy events versus placebo; inclusion of IgE category change increased the apparent benefit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
yght完成签到,获得积分10
刚刚
ICH发布了新的文献求助30
刚刚
1秒前
元元圈圈发布了新的文献求助10
1秒前
1秒前
CC发布了新的文献求助10
1秒前
芷兰发布了新的文献求助10
1秒前
2秒前
jiaying完成签到 ,获得积分10
3秒前
走天涯完成签到 ,获得积分10
3秒前
3秒前
思源的应助被震动的幻丝采纳,获得10
3秒前
传奇3的应助被siraotianya采纳,获得10
3秒前
多多发布了新的文献求助30
4秒前
我是老大的应助被玉龙爬雪山采纳,获得10
4秒前
潇洒的小诸葛完成签到,获得积分10
4秒前
4秒前
5秒前
是法国发布了新的文献求助10
5秒前
英姑的应助被muyan采纳,获得10
5秒前
maxvesterpan发布了新的文献求助10
6秒前
6秒前
6秒前
暮商发布了新的文献求助10
6秒前
8秒前
8秒前
9秒前
豆豆完成签到,获得积分10
9秒前
60发布了新的文献求助10
9秒前
9秒前
aikeyan完成签到 ,获得积分10
9秒前
钉钉发布了新的文献求助10
9秒前
jun发布了新的文献求助10
10秒前
小蘑菇的应助被狂野的怜翠采纳,获得10
10秒前
yy完成签到,获得积分10
11秒前
共享精神的应助被樱桃小丸子采纳,获得30
11秒前
11秒前
LIUYONG发布了新的文献求助50
12秒前
十四完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175478
求助须知:如何正确求助?哪些是违规求助? 9567210
关于积分的说明 21791114
捐赠科研通 7770034
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556237
邀请新用户注册赠送积分活动 2477293